Infectious-inflammatory diseases of the respiratory tract take the first place in the structure of infectious pathology. Thereby, the problem of the rational choice of an antibacterial agent for the treatment of lower respiratory tract infections remains urgent.
The choice of a drug for antibacterial therapy should be based on its spectrum of action, encompassing an isolated or presumed causative agent susceptible to this antibiotic, the pharmacokinetic properties of the antibacterial agent, providing its penetration into therapeutic concentrations in appropriate tissues, cells and body fluids, antibiotic safety data, drug characteristics form, the mode of dosing administration and regimen, providing high compliance of therapy, the pharmacoeconomic aspects of treatment.
Zithromax (Azithromycin) is a medication that is often prescribed in the treatment of bronchitis. This is due to its high concentration in the bronchi in a short time after the drug admission and a long elimination of half-life, which makes antibiotic therapy short-lived. The positive feedback about the drug is due to the lack of postantibiostatic effect in adults. For example, it does not have a pernicious effect on the intestinal microflora.
Within 10 years, the effectiveness of Zithromax in lower respiratory tract infections was studied in 29 large randomized controlled trials in 5,901 patients, including 762 children.
The effectiveness of both a 3-day and 5-day course of Azithromycin was high and in most studies was comparable to a 10-day course of treatment with reference drugs.
In 5 studies, Azithromycin was superior in effectiveness to comparators (co-amoxiclav, erythromycin, benzylpenicillin, and ceftibuten). The tolerability of therapy in the main and control groups was generally comparable, although in 4 studies Azithromycin caused undesirable effects less often than co-amoxiclav or cefuroxime axetil.
The difference was mainly due to a lower incidence of gastrointestinal disorders in the treatment of Zithromax.